Related Experiment Videos
Ovarian serous borderline tumors with invasive peritoneal implants
D M Gershenson1, E G Silva, L Levy
1Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Cancer
|March 20, 1998
Summary
Ovarian serous borderline tumors with invasive peritoneal implants often recur as serous carcinoma. Macroscopic residual disease significantly predicts poor survival, while the role of postoperative therapy remains unclear.
Area of Science:
- Gynecologic Oncology
- Pathology
- Surgical Oncology
Background:
- Ovarian serous borderline tumors (SBTs) with invasive peritoneal implants represent a unique clinical challenge.
- Understanding their behavior and the impact of treatment is crucial for patient management.
Purpose of the Study:
- To update experience with ovarian SBTs and invasive peritoneal implants.
- To gain insight into tumor biology and the effect of postoperative treatment.
Main Methods:
- Retrospective review of 39 patients with ovarian SBTs and invasive peritoneal implants.
- Analysis of endpoints including response, recurrence, progression-free survival (PFS), and overall survival.
- Univariate and multivariate regression analyses were performed.
Main Results:
- 31% of patients experienced disease progression or recurrence, most commonly as invasive low-grade serous carcinoma.
- Macroscopic residual disease was the sole significant predictor of survival (P < 0.01).
- Platinum-based chemotherapy was associated with shorter PFS.
Conclusions:
- Over 30% of patients develop recurrent or progressive disease, frequently serous carcinoma.
- Macroscopic residual disease is a key predictor of recurrence and survival.
- The role and selection criteria for postoperative therapy require further investigation.